Abstract:Cigarette smoke, a toxic collection of more than 4000 chemicals generated from combustion of tobacco plant leaves, is known to cause several respiratory ailments, including chronic bronchitis, emphysema and lung cancer, and is associated with an increase in respiratory infections. In addition, cigarette smoking is considered a principal aetiological factor responsible for the development of certain diffuse interstitial and bronchiolar lung diseases, namely respiratory bronchiolitis-interstitial lung disease (RB-ILD), desquamative interstitial pneumonia (DIP) and adult pulmonary Langerhans’ cell histiocytosis (PLCH). Although not exclusively seen in cigarette smokers, substantial clinical and epidemiological data support a central role for smoking as the primary causative agent of most RB-ILD, DIP and PLCH. Additional evidence in support of cigarette smoke as a primary aetiological agent in RB-ILD, DIP and PLCH is the observation that smoking cessation may lead to disease improvement, while recurrence of these disorders has been observed to occur in the transplanted lung upon re-exposure to tobacco smoke. Furthermore, histopathological changes of respiratory bronchiolitis, DIP and PLCH (with or without co-existent emphysema) may be found on lung biopsy in the same individual, implicating smoking as a common inciting agent of these diverse lesions. Recent studies also suggest a role for cigarette smoking as a potential co-factor in the development of acute eosinophilic pneumonia, usual interstitial pneumonia and rheumatoid arthritis-associated interstitial lung disease. In the current review, we propose a novel classification that takes into account the complex relationship between cigarette smoking and diffuse lung diseases. Investigation on the role of smoking as a potential causative factor or modifier of these diverse diffuse lung diseases is important, as smoking cessation utilizing state-of-the-art tobacco cessation efforts should be a central part of therapy, while pharmacotherapy with corticosteroids or other immune modifying agents should be reserved for selected patients.

Evaluating blood inflammatory cells in smokers and patients with COPD: implications for COPD management

Are healthy smokers really healthy?

The peripheral vascular consequences of smoking

Altered Human Brain Anatomy in Chronic Smokers: a Review of Magnetic Resonance Imaging Studies

Changes in platelet glycoprotein receptors after smoking--a flow cytometric study

Longitudinal Impact of Smoking and Smoking Cessation on Inflammatory Markers of Cardiovascular Disease Risk

POSITIVE AND NEGATIVE ACUTE PHASE REACTANTS IN SMOKERS

Cigarette Smoking and Diffuse Lung Disease

Effects of Smoking on Respiratory System

Lung Deposition Analyses of Inhaled Toxic Aerosols in Conventional and Less Harmful Cigarette Smoke: A Review

[The role of smoking in changing essential parameters in body homeostasis]

The Role of Smoking in the Mechanisms of Development of Chronic Obstructive Pulmonary Disease and Atherosclerosis

Effects of Active Chronic Cigarette-Smoke Exposure on Circulating Fibrocytes

Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches

The cardiovascular effects of electronic cigarettes: A systematic review of experimental studies

Oxidative stress and inflammation: elucidating mechanisms of smoking-attributable pathology for therapeutic targeting

Key role of activated platelets in the enhanced adhesion of circulating leucocyte-platelet aggregates to the dysfunctional endothelium in early-stage COPD

Cigarette smoke exposure and alveolar macrophages: mechanisms for lung disease

Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm

Effect of Cigarette Smoking on Clinical and Molecular Endpoints in COPD Patients